Protocol Ledger

NCT03452137 · Phase III · TERMINATED

A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Interventional Phase III clinical trial protocol NCT03452137 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-04-03 Enrollment: 406 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03452137
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)406 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03452137
Protocol FieldVerified Registry Value
NCT IdentifierNCT03452137
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment406 participants (ACTUAL)
Registered Start Date2018-04-03
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI